Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.53
(
-0.12%
)
Bitcoin
73,756.97
(
-0.25%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 126552

Friday, 05/03/2013 5:41:01 PM

Friday, May 03, 2013 5:41:01 PM

Post# of 257253
TEVA/MNTA—In scanning some old posts, I came across yet another instance of misdirection by Teva’s Bill Marth (who is no longer with the company). Marth said as recently as late 2011 that Teva was still developing the “low volume” formulation of Copaxone: #msg-67094037. We know now that this program is dead, and it was probably dead even then.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now